Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time (5:30 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.
A webcast of the presentation will be live and archived on the Events and Presentation section of the company website.
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. Biocept focuses on cancers that have metastasized into the central nervous system and has developed its proprietary CNSide™ cerebrospinal fluid assay that detects metastatic cancer and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005017/en/
Investor and Media Contact
LHA Investor Relations
Jcain@lhai.com, (310) 691-7100